Letter to the Editor
Copyright ©The Author(s) 2025.
World J Psychiatry. Sep 19, 2025; 15(9): 109363
Published online Sep 19, 2025. doi: 10.5498/wjp.v15.i9.109363
Table 2 Points for further consideration
Focus area
Action
Outcome measure
Longitudinal efficacyBehavioral tests + diffusion MRI at 2, 8, 16 weeksMemory scores; fractional anisotropy
Cell-type specificityGenerate CX3CR1-CreERT2 Hv1flox/flox for microglia-only KO; compare GFAP-Cre astrocyte KOCytokine levels; OPC survival; g-ratio
Pharmacological proof-of-conceptScreen Hv1 inhibitors for IC50, BBB penetration, and toxicity; test alone and with remyelinating agentsPatch-clamp IC50; brain/plasma ratio; maze performance
Mechanistic clarificationpH imaging in microglia under hyperglycemia; Co-IP of Hv1 and NOX2Intracellular pH; ROS assays; protein interaction